Twin Tree Management
RETA

Twin Tree Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Twin Tree Management’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-19,800
Closed -$2.86M – 1761
2020
Q1 		$2.86M Buy
+19,800
New +$3.82M 0.01% 632

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Twin Tree Management's RETA Position: Q2 2020 in Review

Twin Tree Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2020, closing a stake of 10,433 shares — an estimated $1.51M sold.

Twin Tree Management first reported a position in RETA in Q1 2019 and held it in 2 quarters. The position peaked at $1.51M in Q1 2020. 207 funds tracked by Wall St. Rank hold RETA as of Q2 2020.

  • Twin Tree Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2020 after selling out during the quarter.
  • Twin Tree Management sold 10,433 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2020, an estimated $1.51M.
  • Twin Tree Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2019 and held it in 2 quarters.
  • Twin Tree Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.51M in Q1 2020.
  • 207 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2020.

Based on Twin Tree Management's 13F filing for Q2 2020, filed 12 Aug 2020.